Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Oncology

Who Should Be Tested? Understanding Diagnostic Criteria

At a Glance

Genetic testing for familial melanoma is recommended for individuals with multiple melanomas, an early diagnosis before age 40, or a strong family history. Specialists use multigene panels to identify mutations and genetic counselors help interpret results to guide your ongoing cancer screening.

Deciding whether to undergo genetic testing for melanoma is a personal and medical choice. Because most melanomas are not hereditary, doctors use specific clinical “filters” to determine who is most likely to carry a high-risk gene mutation.

Clinical Criteria: The Rule of Twos and Threes

Since there is no single global standard for when to test, many specialists use the “Rule of Two” and “Rule of Three” as a starting point [1][2]. These rules change depending on whether you live in a region where melanoma is very common (high-incidence) or relatively rare (low-incidence).

  • Low-to-Moderate Incidence Regions (e.g., much of Europe): Doctors often use the Rule of Two. You may be referred for testing if you have:
    • Two or more primary melanomas yourself [3].
    • At least two first-degree relatives (parents, siblings, children) or second-degree relatives (grandparents, aunts, uncles, half-siblings) with melanoma or related cancers like pancreatic cancer [3].
  • High-Incidence Regions (e.g., Australia, parts of the US): Doctors often use the Rule of Three. Because sun-related melanoma is so common in these areas, you may need a stronger family history—three or more cases—to suggest a genetic link rather than just environmental exposure [3][2].
  • Early Onset: Regardless of location, a diagnosis before age 40 often lowers the threshold for genetic concern [3].

From Single Genes to Multigene Panels

In the past, genetic testing often looked at only one gene at a time, usually CDKN2A. Today, most experts recommend multigene panel testing [4][5].

Test Type Description Pros/Cons
Single Gene Tests only for a specific mutation (usually CDKN2A). Efficient if a mutation is already known in your family, but misses other rare genes [4].
Multigene Panel Tests many genes at once (CDKN2A, CDK4, BAP1, POT1, TERT, MITF, etc.). Increases the chance of finding a mutation by about 4% in families who previously tested negative [4][6].

While panels are more comprehensive, they also increase the chance of finding a Variant of Uncertain Significance (VUS)—a genetic change where scientists aren’t yet sure if it causes cancer or is just a normal human variation [7][8].

The Role of a Genetic Counselor

A genetic counselor is a specialist who helps you navigate the complexities of testing [9]. Before you provide a DNA sample (usually via blood or saliva), a counselor will:

  • Assess Your Risk: They use specialized software and your family tree to calculate the statistical probability that you carry a mutation [10].
  • Explain Limitations: No genetic test can rule out 100% of cancer risk. Even if your test is negative, your family may still have a “familial” risk that requires close skin monitoring [11][12].
  • Discuss Privacy: They can explain laws like GINA (Genetic Information Nondiscrimination Act), which protect you from health insurance and employment discrimination based on genetic results. Crucially, GINA does not apply to life insurance, disability insurance, or long-term care insurance. Many patients choose to secure these policies before undergoing genetic testing.

Testing and Children

Parents often ask if their children should be tested. Because genes like CDKN2A primarily increase cancer risk in adulthood, genetic testing is typically deferred until a child reaches 18 and can make their own informed decision. However, their skin screening and sun protection habits should begin much earlier.

Formal Diagnosis

A formal diagnosis of familial melanoma is often clinical, based on meeting the criteria mentioned above [12]. A molecular diagnosis (finding a specific mutation) is the “gold standard” because it allows for more targeted screening, such as adding pancreatic imaging if a CDKN2A mutation is confirmed [13][14]. However, many families with a clear pattern of melanoma never find a specific “smoking gun” gene, but are still treated as high-risk [11].

Common questions in this guide

Do I qualify for familial melanoma genetic testing?
Doctors use the Rule of Two or Rule of Three, depending on the melanoma rates where you live. You may qualify if you have had multiple melanomas, were diagnosed before age 40, or have multiple close relatives with melanoma or pancreatic cancer.
What is a multigene panel for melanoma?
A multigene panel tests for several genetic mutations linked to melanoma at once, such as CDKN2A, BAP1, and CDK4. This comprehensive approach increases the chances of identifying a hereditary cancer risk compared to testing just a single gene.
Should my children be tested for familial melanoma genes?
Because melanoma-related genes primarily increase cancer risk in adulthood, experts usually recommend waiting until a child is 18 to make their own decision about genetic testing. However, strict sun protection and regular skin checks should begin much earlier.
What does a Variant of Uncertain Significance (VUS) mean?
A VUS is a genetic change found during testing where scientists are not yet sure if it increases cancer risk or is just a normal human variation. Your genetic counselor and doctor will help you understand what this uncertain result means for your medical care.
Will genetic testing affect my insurance coverage?
Laws like the Genetic Information Nondiscrimination Act (GINA) protect you from health insurance and employment discrimination based on genetic test results. Crucially, this protection does not apply to life insurance, disability insurance, or long-term care insurance.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific family history and where we live, do I meet the clinical 'Rule of Two' or 'Rule of Three'?
  2. 2.If I test negative for the most common gene (CDKN2A), will you order a larger multigene panel?
  3. 3.How many of my first-degree relatives should be screened if my genetic test comes back positive?
  4. 4.If the test finds a 'Variant of Uncertain Significance' (VUS), how will that change my medical care or screening?
  5. 5.Can you provide a referral to a genetic counselor to help me interpret these results before I proceed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Identification, genetic testing, and management of hereditary melanoma.

    Leachman SA, Lucero OM, Sampson JE, et al.

    Cancer metastasis reviews 2017; (36(1)):77-90 doi:10.1007/s10555-017-9661-5.

    PMID: 28283772
  2. 2

    Molecular landscape of Hereditary Melanoma.

    Ribeiro Moura Brasil Arnaut J, Dos Santos Guimarães I, Evangelista Dos Santos AC, et al.

    Critical reviews in oncology/hematology 2021; (164()):103425 doi:10.1016/j.critrevonc.2021.103425.

    PMID: 34245855
  3. 3

    Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.

    Delaunay J, Martin L, Bressac-de Paillerets B, et al.

    JAMA dermatology 2017; (153(11)):1122-1129 doi:10.1001/jamadermatol.2017.2926.

    PMID: 28903138
  4. 4

    Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.

    Potjer TP, Bollen S, Grimbergen AJEM, et al.

    International journal of cancer 2019; (144(10)):2453-2464 doi:10.1002/ijc.31984.

    PMID: 30414346
  5. 5

    Genetic testing for inherited colorectal cancer and polyposis, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG).

    Mao R, Krautscheid P, Graham RP, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(10)):1807-1817 doi:10.1038/s41436-021-01207-9.

    PMID: 34140662
  6. 6

    Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1.

    Pastorino L, Andreotti V, Dalmasso B, et al.

    Cancers 2020; (12(4)) doi:10.3390/cancers12041007.

    PMID: 32325837
  7. 7

    Improving genetic diagnosis of hereditary tumor syndromes: From expanded gene panels to functional genomics.

    Sauer M, Lucas MC, Prokosch V, et al.

    International journal of cancer 2025; doi:10.1002/ijc.70274.

    PMID: 41347847
  8. 8

    Routine use of gene panel testing in hereditary breast cancer should be performed with caution.

    van Marcke C, De Leener A, Berlière M, et al.

    Critical reviews in oncology/hematology 2016; (108()):33-39 doi:10.1016/j.critrevonc.2016.10.008.

    PMID: 27931838
  9. 9

    Genetic testing for familial melanoma.

    Primiero CA, Maas EJ, Wallingford CK, et al.

    Italian journal of dermatology and venereology 2024; (159(1)):34-42 doi:10.23736/S2784-8671.23.07761-7.

    PMID: 38287743
  10. 10

    Protocol to evaluate a pilot program to upskill clinicians in providing genetic testing for familial melanoma.

    Primiero CA, Finnane A, Yanes T, et al.

    PloS one 2022; (17(12)):e0275926 doi:10.1371/journal.pone.0275926.

    PMID: 36477719
  11. 11

    The Interplay between Nevi and Melanoma Predisposition Unravels Nevi-Related and Nevi-Resistant Familial Melanoma.

    Pellegrini S, Elefanti L, Dall'Olmo L, Menin C

    Genes 2021; (12(7)) doi:10.3390/genes12071077.

    PMID: 34356093
  12. 12

    Germline mutations predisposing to melanoma and associated malignancies and syndromes: a narrative review.

    López Riquelme I, Martínez García S, Serrano Ordónez A, Martínez Pilar L

    International journal of dermatology 2025; (64(6)):1027-1041 doi:10.1111/ijd.17602.

    PMID: 39651613
  13. 13

    CDKN2A Gene Mutations: Implications for Hereditary Cancer Syndromes.

    Danishevich A, Bilyalov A, Nikolaev S, et al.

    Biomedicines 2023; (11(12)) doi:10.3390/biomedicines11123343.

    PMID: 38137564
  14. 14

    Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants.

    Pauley K, Khan A, Kohlmann W, Jeter J

    Frontiers in oncology 2022; (12()):837057 doi:10.3389/fonc.2022.837057.

    PMID: 35372037

This page provides educational information about familial melanoma diagnostic criteria and genetic testing. It does not replace professional medical advice; always consult a genetic counselor or oncologist regarding your specific genetic risk.

Get notified when new evidence is published on Familial melanoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.